$415 Million is the total value of Ikarian Capital, LLC's 86 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IVA | Exit | INVENTIVA SAads | $0 | – | -13,236 | -100.0% | -0.01% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -4,064 | -100.0% | -0.02% | – |
| MITO | Exit | STEALTH BIOTHERAPEUTICS CORPsponsored ads | $0 | – | -435,516 | -100.0% | -0.03% | – |
| PRAX | Exit | PRAXIS PRECISION MEDICINES Icall | $0 | – | -74,200 | -100.0% | -0.03% | – |
| GOSS | Exit | GOSSAMER BIO INCput | $0 | – | -17,400 | -100.0% | -0.04% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -361,518 | -100.0% | -0.09% | – |
| CLNN | Exit | CLENE INCput | $0 | – | -177,400 | -100.0% | -0.10% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -2,800 | -100.0% | -0.11% | – |
| Exit | RENOVACOR INC | $0 | – | -288,119 | -100.0% | -0.14% | – | |
| MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -131,310 | -100.0% | -0.17% | – |
| BLU | Exit | BELLUS HEALTH INC NEWcall | $0 | – | -85,200 | -100.0% | -0.18% | – |
| CLNN | Exit | CLENE INCcall | $0 | – | -322,600 | -100.0% | -0.18% | – |
| AKRO | Exit | AKERO THERAPEUTICS INCcall | $0 | – | -40,900 | -100.0% | -0.28% | – |
| Exit | CINCOR PHARMA INC | $0 | – | -45,100 | -100.0% | -0.30% | – | |
| MIST | Exit | MILESTONE PHARMACEUTICALS INcall | $0 | – | -180,300 | -100.0% | -0.33% | – |
| INSM | Exit | INSMED INCcall | $0 | – | -100,000 | -100.0% | -0.43% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS INcall | $0 | – | -122,600 | -100.0% | -0.45% | – |
| STSA | Exit | SATSUMA PHARMACEUTICALS INCcall | $0 | – | -400,000 | -100.0% | -0.48% | – |
| RVNC | Exit | REVANCE THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -0.54% | – |
| MIST | Exit | MILESTONE PHARMACEUTICALS INput | $0 | – | -338,000 | -100.0% | -0.62% | – |
| SCPH | Exit | SCPHARMACEUTICALS INC | $0 | – | -479,383 | -100.0% | -0.62% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcall | $0 | – | -138,100 | -100.0% | -0.69% | – |
| PRTA | Exit | PROTHENA CORP PLCcall | $0 | – | -66,800 | -100.0% | -0.81% | – |
| STOK | Exit | STOKE THERAPEUTICS INCput | $0 | – | -368,700 | -100.0% | -0.94% | – |
| CERE | Exit | CEREVEL THERAPEUTICS HLDNG I | $0 | – | -178,100 | -100.0% | -1.00% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB Lcall | $0 | – | -85,100 | -100.0% | -1.05% | – |
| GOSS | Exit | GOSSAMER BIO INCcall | $0 | – | -526,600 | -100.0% | -1.26% | – |
| Exit | AMYLYX PHARMACEUTICALS INCcall | $0 | – | -250,000 | -100.0% | -1.40% | – | |
| TCDA | Exit | TRICIDA INCput | $0 | – | -727,900 | -100.0% | -1.52% | – |
| ISEE | Exit | IVERIC BIO INCcall | $0 | – | -437,900 | -100.0% | -1.56% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INCcall | $0 | – | -85,200 | -100.0% | -1.88% | – |
| Exit | DICE THERAPEUTICS INCput | $0 | – | -504,100 | -100.0% | -2.04% | – | |
| BIIB | Exit | BIOGEN INCput | $0 | – | -53,200 | -100.0% | -2.83% | – |
| Exit | DICE THERAPEUTICS INCcall | $0 | – | -748,900 | -100.0% | -3.03% | – | |
| AXSM | Exit | AXSOME THERAPEUTICS INCput | $0 | – | -407,600 | -100.0% | -3.62% | – |
| SGEN | Exit | SEAGEN INCcall | $0 | – | -150,000 | -100.0% | -4.09% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -60,000 | -100.0% | -4.27% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INCcall | $0 | – | -775,300 | -100.0% | -5.72% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INCput | $0 | – | -775,300 | -100.0% | -5.72% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 15 | Q2 2023 | 1.5% |
| OCULAR THERAPEUTIX INC | 15 | Q3 2023 | 1.4% |
| SAREPTA THERAPEUTICS INC | 14 | Q3 2023 | 6.4% |
| X4 PHARMACEUTICALS INC - PIPE | 14 | Q2 2023 | 1.4% |
| PROTARA THERAPEUTICS INC | 14 | Q3 2023 | 1.2% |
| SPDR SER TR | 13 | Q3 2023 | 9.0% |
| VAXCYTE INC | 13 | Q3 2023 | 2.9% |
| TRACON PHARMACEUTICALS INC | 13 | Q3 2023 | 1.4% |
| MILESTONE PHARMACEUTICALS IN | 13 | Q3 2023 | 1.7% |
| BELLUS HEALTH INC NEW | 13 | Q1 2023 | 1.8% |
View Ikarian Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 460,416 | 1.3% |
| X4 Pharmaceuticals, Inc | February 14, 2023 | 349,133 | 0.3% |
| aTYR PHARMA INC | February 14, 2022 | 35,048 | 0.1% |
| Cyclacel Pharmaceuticals, Inc. | February 14, 2022 | 99,422 | 1.0% |
| KalVista Pharmaceuticals, Inc. | February 14, 2022 | 36,576 | 0.2% |
| Lyra Therapeutics, Inc. | February 14, 2022 | 394,536 | 3.0% |
| Odonate Therapeutics, Inc. | February 14, 2022 | 1,340,631 | 3.5% |
| Protara Therapeutics, Inc. | February 14, 2022 | 279,256 | 2.5% |
| Science 37 Holdings, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| scPharmaceuticals Inc. | February 14, 2022 | 901,362 | 3.3% |
View Ikarian Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View Ikarian Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.